

UW Medicine and Fred Hutch Cancer Center Clinical Algorithm for Outpatient COVID-19 Therapeutics

Useful Resources (links below):

NIH Guidelines

Adult or pediatric (age 12 and older and weight 40kg or greater) with a current diagnosis of mild to moderate (i.e. symptomatic) COVID-19 & high risk for progression to severe disease

YES

Is the Patient:
Hospitalized for COVID-19 **OR**
Requiring O₂ **OR** an increase in baseline home O₂ due to COVID-19

YES

Management per NIH & UW Guidelines

NO

Symptom onset within 5-7 days* AND immunocompetent?
*day of symptom onset = day 0

YES

Does patient have severe renal impairment (eGFR <30mL/min) **OR** severe hepatic impairment (child-pugh class C)?

YES

Consider the following:
(symptoms within 5 days):

Immunocompetent: supportive care or evaluate for molnupiravir*

YES

Solid organ or bone marrow transplant pt and within 7 days of symptom onset*: individual organ transplant teams should use SOTIDCOVIDNOTIFY dotphrase and then place REDCAP.

OR

Immunosuppressed and within 5 days of symptom onset: Paxlovid if no other contraindication
* DO NOT give to SOLID ORGAN TRANSPLANT pts without consultation with transplant pharmacist*

*SOT: If pt presents to ED, give remdesivir x 1 & refer to SOT guidelines below. Subsequent doses will be scheduled M-F. Page SOT ID on weekends, if needed. FHCC: coordinate with primary team.

NO

Consider one of the following therapeutics, if available:

Paxlovid within 5 days of symptom onset
eGFR 60 mL/min or greater: 300mg nirmatrelvir taken with 100mg ritonavir twice daily for 5 days
eGFR ≥30-≤60: 150mg nirmatrelvir taken together with 100mg ritonavir twice daily for 5 days;

Evaluate concomitant medications prior to prescribing
<https://www.covid19-druginteractions.org/>
(DO NOT give to SOLID ORGAN TRANSPLANT)

If none of the above therapeutics are available for patient treatment within 5 days of symptom onset and patient is **age 18 or greater**

YES

Possibility of pregnancy (if applicable) is ruled out?

NO

Management per NIH & UW Guidelines

Consider molnupiravir

Authorized only in patients ages 18 and older;
No dose adjustment for renal or hepatic function
Give within 5 days of symptom onset
Molnupiravir 800mg by mouth every 12h for 5 days
Prescribers must review and comply with the mandatory requirements outlined in the molnupiravir EUA

NO, immunosuppressed

Symptom onset within 5-7 days AND immunosuppressed?
*day of symptom onset = day 0

YES

Management per NIH & UW Guidelines

NO